License with Intima Bioscience

RNS Number : 2329A

MaxCyte, Inc.

01 February 2022

 

MaxCyte Signs Strategic Platform License with Intima Bioscience

to Advance Tumor Infiltrating Lymphocytes Programs

Intima Bioscience to use MaxCyte's Flow Electroporation ® technology and ExPERT™ platform to accelerate the development of its solid tumor cell-therapy candidates

New yorK City, NY and GAITHERSBURG, MD, Feb. 1, 2022 - MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell engineering, today announces the signing of a strategic platform license (SPL) with Intima Bioscience, Inc., a clinical stage biotechnology company developing genetically engineered cell therapies for solid tumor cancer. Intima joins a group of 15 other leading cell therapy companies who have partnered with MaxCyte.

Under the terms of the agreement, Intima obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related milestone payments.

Intima is currently running a Phase 1/2 clinical study (NCT04426669) of its lead checkpoint cell therapy candidate, which targets the immune checkpoint CISH in patients with gastrointestinal and colon cancers.

"As we advance our innovative eTIL CISH knock out programs, we are preparing for the future by securing access to MaxCyte's  industry leading cellular engineering technology," said Alessandro Riva, M.D., Intima CEO.

Doug Doerfler, President and CEO of MaxCyte , said: "We are proud to be working with Intima, a cell therapy leader leveraging the unique power of genetically engineered tumor infiltrating lymphocytes (eTIL). This relationship represents an important achievement for MaxCyte as it expands the use of our next-generation technology platform to support engineering in additional novel cell types."

MaxCyte's ExPERT™ instrument portfolio is the next generation of leading, clinically-validated, electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT™ platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. Intima Bioscience is MaxCyte's 16th SPL which generate pre-commercial milestone revenue and the vast majority of which include post-commercial revenue.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation^® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

About Intima Bioscience

Intima Bioscience is a company advancing checkpoint cell therapy, an approach that combines the use of patients' own immune cells with immune checkpoint targeting, in solid tumors with curative intent. Intima is currently running a  Phase 1/2 clinical study  of its checkpoint cell therapy, which targets the immune checkpoint CISH in patients with gastrointestinal and colon cancers. 

MaxCyte Contacts:

US IR Adviser Gilmartin Group David Deuchler, CFA	[phone]   [e-mail]
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden	[phone]
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh	[phone] [e-mail]

 

END

 

 

MSCSDAEEFEESELF